{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:49:56Z","timestamp":1791661796912,"version":"4.3.4"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1R01NS096376"],"award-info":[{"award-number":["1R01NS096376"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1R01NS112856"],"award-info":[{"award-number":["1R01NS112856"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["P50CA221747"],"award-info":[{"award-number":["P50CA221747"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["5R01NS110703"],"award-info":[{"award-number":["5R01NS110703"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hoc.2026.09.002","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:12:12Z","timestamp":1791580332000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Purine Metabolism as a Therapeutic Target in Glioblastoma"],"prefix":"10.1016","author":[{"given":"Noah B.","family":"Drewes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya U.","family":"Kumthekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atique U.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.hoc.2026.09.002_bib1","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.hoc.2026.09.002_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.hoc.2026.09.002_bib3","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/annonc\/mdx169","article-title":"Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma","volume":"28","author":"Qazi","year":"2017","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2026.09.002_bib4","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1016\/j.cell.2024.05.011","article-title":"De novo and salvage purine synthesis pathways across tissues and tumors","volume":"187","author":"Tran","year":"2024","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.002_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","article-title":"Nucleotide metabolism: a pan-cancer metabolic dependency","volume":"23","author":"Mullen","year":"2023","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.002_bib6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.002_bib7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nn.4537","article-title":"Purine synthesis promotes maintenance of brain tumor initiating cells in glioma","volume":"20","author":"Wang","year":"2017","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.002_bib8","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1038\/s41467-020-17512-x","article-title":"Purine metabolism regulates DNA repair and therapy resistance in glioblastoma","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.hoc.2026.09.002_bib9","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/brain\/awab020","article-title":"De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma","volume":"144","author":"Shireman","year":"2021","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.002_bib10","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1038\/s41467-022-32430-w","article-title":"Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma","volume":"13","author":"Coy","year":"2022","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.hoc.2026.09.002_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087027","article-title":"Purine metabolism dysfunctions: experimental methods of detection and diagnostic potential","volume":"24","author":"Cicero","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.002_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41392-021-00553-z","article-title":"From purines to purinergic signalling: molecular functions and human diseases","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.002_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10409238.2020.1832438","article-title":"Human de novo purine biosynthesis","volume":"56","author":"Pareek","year":"2021","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"11","key":"10.1016\/j.hoc.2026.09.002_bib14","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1074\/jbc.M114.628701","article-title":"Quantitative analysis of purine nucleotides indicates that purinosomes increase de novo purine biosynthesis","volume":"290","author":"Zhao","year":"2015","journal-title":"J Biol Chem"},{"issue":"28","key":"10.1016\/j.hoc.2026.09.002_bib15","doi-asserted-by":"crossref","first-page":"9551","DOI":"10.1074\/jbc.RA119.012175","article-title":"Hypoxia drives the assembly of the multienzyme purinosome complex","volume":"295","author":"Doigneaux","year":"2020","journal-title":"J Biol Chem"},{"issue":"40","key":"10.1016\/j.hoc.2026.09.002_bib16","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1039\/c3cc41437j","article-title":"The purinosome, a multi-protein complex involved in the de novo biosynthesis of purines in humans","volume":"49","author":"Zhao","year":"2013","journal-title":"Chem Commun"},{"issue":"51","key":"10.1016\/j.hoc.2026.09.002_bib17","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1073\/pnas.1814042115","article-title":"Microtubule-directed transport of purine metabolons drives their cytosolic transit to mitochondria","volume":"115","author":"Chan","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hoc.2026.09.002_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109370","article-title":"The mammalian purine salvage pathway as an exploitable route for cerebral bioenergetic support after brain injury","volume":"224","author":"Gessner","year":"2023","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.hoc.2026.09.002_bib19","first-page":"F1058","article-title":"Na(+)-dependent purine nucleoside transporter from human kidney: cloning and functional characterization","volume":"273","author":"Wang","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.hoc.2026.09.002_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/srep15057","article-title":"Functional identification of SLC43A3 as an equilibrative nucleobase transporter involved in purine salvage in mammals","volume":"5","author":"Furukawa","year":"2015","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.hoc.2026.09.002_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107524","article-title":"Significance and amplification methods of the purine salvage pathway in human brain cells","volume":"300","author":"Sekine","year":"2024","journal-title":"J Biol Chem"},{"key":"10.1016\/j.hoc.2026.09.002_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1434118","article-title":"Unlocking the adenosine receptor mechanism of the tumour immune microenvironment","volume":"15","author":"Han","year":"2024","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.hoc.2026.09.002_bib23","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/neuonc\/not067","article-title":"Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas","volume":"15","author":"Xu","year":"2013","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2026.09.002_bib24","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41419-021-04359-3","article-title":"CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis"},{"issue":"13","key":"10.1016\/j.hoc.2026.09.002_bib25","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1158\/0008-5472.CAN-18-1010","article-title":"MTAP loss promotes stemness in glioblastoma and confers unique susceptibility to purine starvation","volume":"79","author":"Hansen","year":"2019","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2026.09.002_bib26","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/s41419-024-07170-y","article-title":"One-carbon-mediated purine synthesis underlies temozolomide resistance in glioblastoma","volume":"15","author":"Ghannad-Zadeh","year":"2024","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.002_bib27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41419-021-03543-9","article-title":"Rewiring of purine metabolism in response to acidosis stress in glioma stem cells","volume":"12","author":"Xu","year":"2021","journal-title":"Cell Death Dis"},{"issue":"10","key":"10.1016\/j.hoc.2026.09.002_bib28","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1021\/acs.chemrestox.5c00196","article-title":"Temozolomide-derived AIC is incorporated into purine synthesis in glioblastoma","volume":"38","author":"Sowers","year":"2025","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.002_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40478-020-01114-1","article-title":"Glioma cells require one-carbon metabolism to survive glutamine starvation","volume":"9","author":"Tanaka","year":"2021","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.002_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020310","article-title":"Targeting glutamine addiction in gliomas","volume":"12","author":"Obara-Michlewska","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.hoc.2026.09.002_bib31","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/ncb3272","article-title":"Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma","volume":"17","author":"Tardito","year":"2015","journal-title":"Nat Cell Biol"},{"issue":"6","key":"10.1016\/j.hoc.2026.09.002_bib32","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.cmet.2017.10.001","article-title":"In vivo imaging of glutamine metabolism to the oncometabolite 2-Hydroxyglutarate in IDH1\/2 mutant tumors","volume":"26","author":"Salamanca-Cardona","year":"2017","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.002_bib33","article-title":"The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling","volume":"3","author":"Yamashita","year":"2021","journal-title":"Neurooncol Adv"},{"issue":"8","key":"10.1016\/j.hoc.2026.09.002_bib34","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s41556-019-0363-9","article-title":"IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma","volume":"21","author":"Kofuji","year":"2019","journal-title":"Nat Cell Biol"},{"issue":"7","key":"10.1016\/j.hoc.2026.09.002_bib35","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.7150\/thno.124409","article-title":"Coupling proteostasis and de novo purine biosynthesis of PSMD14 fuels glioblastoma progression and chemoresistance","volume":"16","author":"Wang","year":"2026","journal-title":"Theranostics"},{"issue":"8042","key":"10.1016\/j.hoc.2026.09.002_bib36","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41586-024-08224-z","article-title":"Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma","volume":"636","author":"Chen","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.002_bib37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1186\/s12967-022-03823-8","article-title":"MTAP loss: a possible therapeutic approach for glioblastoma","volume":"20","author":"Patro","year":"2022","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.002_bib38","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.002_bib39","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/CCO.0000000000000870","article-title":"Targeting the methionine-methionine adenosyl transferase 2A- S -adenosyl methionine axis for cancer therapy","volume":"34","author":"Guo","year":"2022","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.002_bib40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41420-025-02545-2","article-title":"Combined inhibition by PRMT5 and MAT2A demonstrates a strong synthetic lethality in MTAP homozygous-deficient glioma models","volume":"11","author":"Jiang","year":"2025","journal-title":"Cell Death Discov"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.002_bib41","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/onc.2016.199","article-title":"PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells","volume":"36","author":"Banasavadi-Siddegowda","year":"2017","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.hoc.2026.09.002_bib42","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/neuonc\/nox206","article-title":"PRMT5 as a druggable target for glioblastoma therapy","volume":"20","author":"Banasavadi-Siddegowda","year":"2018","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.002_bib43","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1038\/s41467-021-24240-3","article-title":"Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine","volume":"12","author":"Barekatain","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2026.09.002_bib44","article-title":"Adenosinergic signaling as a key modulator of the glioma microenvironment and reactive astrocytes","volume":"15","author":"Debom","year":"2021","journal-title":"Front Neurosci"},{"issue":"10","key":"10.1016\/j.hoc.2026.09.002_bib45","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1096\/fj.08-107458","article-title":"Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function","volume":"22","author":"Cs\u00f3ka","year":"2008","journal-title":"FASEB J"},{"key":"10.1016\/j.hoc.2026.09.002_bib46","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fimmu.2014.00304","article-title":"Extracellular adenosine-mediated modulation of regulatory T cells","volume":"5","author":"Ohta","year":"2014","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.002_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2023.152362","article-title":"Adenosine receptor activation promotes macrophage class switching from LPS-induced acute inflammatory M1 to anti-inflammatory M2 phenotype","volume":"228","author":"Devi","year":"2023","journal-title":"Immunobiology"},{"issue":"9","key":"10.1016\/j.hoc.2026.09.002_bib48","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00262-020-02569-w","article-title":"Blockade of CD73 delays glioblastoma growth by modulating the immune environment","volume":"69","author":"Azambuja","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"10.1016\/j.hoc.2026.09.002_bib49","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1038\/s41401-025-01585-9","article-title":"CD73 inhibitor AB680 suppresses glioblastoma in mice by inhibiting purine metabolism and promoting P2RY12(+) microglia transformation","volume":"46","author":"Gao","year":"2025","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.002_bib50","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12987-017-0088-8","article-title":"The effect of an adenosine A(2A) agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma","volume":"15","author":"Jackson","year":"2018","journal-title":"Fluids Barriers CNS"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.002_bib51","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3171\/jns.1973.39.3.0315","article-title":"Postoperative intracavitary chemotherapy of malignant gliomas. A preliminary study using methotrexate","volume":"39","author":"Garfield","year":"1973","journal-title":"J Neurosurg"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.002_bib52","first-page":"921","article-title":"Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas","volume":"39","author":"Kyritsis","year":"1996","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.002_bib53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/S0317167100029966","article-title":"Phase II study of trimetrexate in recurrent anaplastic glioma. National Cancer Institute of Canada Clinical Trials Group Study","volume":"17","author":"Cairncross","year":"1990","journal-title":"Can J Neurol Sci"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.002_bib54","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1227\/00006123-199105000-00023","article-title":"Continuous intratumoral infusion of methotrexate for recurrent glioblastoma: a pilot study","volume":"28","author":"Nierenberg","year":"1991","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.002_bib55","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11060-010-0313-7","article-title":"Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma","volume":"102","author":"Walbert","year":"2011","journal-title":"J Neuro Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.002_bib56","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11060-010-0334-2","article-title":"High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study","volume":"102","author":"Wolff","year":"2011","journal-title":"J Neuro Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.09.002_bib57","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/BF00686294","article-title":"Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas","volume":"30","author":"Smith","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.002_bib58","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/00000421-198810000-00015","article-title":"Evaluation of fludarabine phosphate in patients with recurrent glioma","volume":"11","author":"Cascino","year":"1988","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.002_bib59","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/bjc.1995.407","article-title":"A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma","volume":"72","author":"Bleehen","year":"1995","journal-title":"Br J Cancer"},{"issue":"36","key":"10.1016\/j.hoc.2026.09.002_bib60","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.1200\/JCO.2005.03.2185","article-title":"Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme","volume":"23","author":"Reardon","year":"2005","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2026.09.002_bib61","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1002\/cncr.26541","article-title":"Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma","volume":"118","author":"Reardon","year":"2012","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.002_bib62","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00000421-199510000-00019","article-title":"Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study","volume":"18","author":"Jeremic","year":"1995","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.002_bib63","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11060-007-9408-1","article-title":"Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas","volume":"85","author":"Shah","year":"2007","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.hoc.2026.09.002_bib64","unstructured":"A phase I trial combining triapine with radiation therapy for recurrent glioblastoma or Astrocytoma. National Library of medicine (US), Available at: https:\/\/clinicaltrials.gov\/study\/NCT06860594 (Accessed 20 April 2026)."},{"key":"10.1016\/j.hoc.2026.09.002_bib65","unstructured":"A phase 1 adaptive dose escalation with dose expansion Study of triapine in combination with Temozolomide (TMZ) for patients with recurrent glioblastoma. National Library of medicine (US), Available at: https:\/\/clinicaltrials.gov\/study\/NCT06410248 (Accessed 20 April 2026)."},{"key":"10.1016\/j.hoc.2026.09.002_bib66","unstructured":"Phase 0\/I dose escalation study of mycophenolate mofetil combined with radiation therapy in glioblastoma. National Library of medicine (US), Available at: https:\/\/clinicaltrials.gov\/study\/NCT04477200 (Accessed 20 April 2026)."},{"key":"10.1016\/j.hoc.2026.09.002_bib67","unstructured":"A phase 1\/1b adaptive dose escalation Study of Mycophenolate Mofetil (MMF) in combination with standard of care for patients with glioblastoma. National Library of medicine (US), Available at: https:\/\/clinicaltrials.gov\/study\/NCT05236036 (Accessed 20 April 2026)."},{"key":"10.1016\/j.hoc.2026.09.002_bib68","article-title":"Adaptive nuclear GTP synthesis promotes glioblastoma treatment resistance and is a targetable vulnerability in patients","author":"Scott","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.hoc.2026.09.002_bib69","unstructured":"A phase I\/II, open-label, non-randomized, multicenter, single agent study of intravenous SDX-102 for the treatment of patients with MTAP-deficient high grade recurrent malignant gliomas. National Library of medicine (US), Available at: https:\/\/clinicaltrials.gov\/study\/NCT00075894 (Accessed 20 April 2026)."},{"key":"10.1016\/j.hoc.2026.09.002_bib70","unstructured":"A phase 0\/1 Study of BMS-986504, a MTA cooperative PRMT5 inhibitor in recurrent glioblastoma participants with MTAP deleted tumors scheduled for resection to evaluate Central Nervous System (CNS) penetration with PK-Triggered expansion cohort. National Library of medicine (US), Available at: https:\/\/clinicaltrials.gov\/study\/NCT06883747 (Accessed 20 April 2026)."},{"key":"10.1016\/j.hoc.2026.09.002_bib71","unstructured":"A phase 1\/1b\/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of anvumetostat alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors. National Library of medicine (US), Available at: https:\/\/clinicaltrials.gov\/study\/NCT05094336 (Accessed 20 April 2026)."},{"key":"10.1016\/j.hoc.2026.09.002_bib72","unstructured":"A phase 1\/2, open-label, multicenter clinical trial investigating the safety, tolerability, pharmacokinetics, and antineoplastic activity of S095035 (MAT2A inhibitor) as a single agent and in combination in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP. National Library of medicine (US), Available at: https:\/\/clinicaltrials.gov\/study\/NCT06188702 (Accessed 20 April 2026)."},{"key":"10.1016\/j.hoc.2026.09.002_bib73","unstructured":"A phase 1\/2, Multi-Center, open-label study to evaluate the safety, tolerability, and preliminary anti-tumor activity of TNG462 as a single agent and in combination in patients with MTAP-deleted advanced or metastatic solid tumors. National Library of medicine (US), Available at: https:\/\/clinicaltrials.gov\/study\/NCT05732831 (Accessed 20 April 2026)."},{"key":"10.1016\/j.hoc.2026.09.002_bib74","unstructured":"A phase 1\/2, Multi-Center, open-label Study to evaluate the safety, tolerability, and preliminary anti-tumor activity of TNG908 in patients with MTAP-deleted advanced or metastatic solid tumors. National Library of medicine (US), Available at: https:\/\/clinicaltrials.gov\/study\/NCT05275478 (Accessed 20 April 2026)."},{"key":"10.1016\/j.hoc.2026.09.002_bib75","unstructured":"A phase 1\/2, multicenter, open-label study to evaluate the safety, tolerability, and preliminary antitumor activity of TNG456 monotherapy and in combination with abemaciclib in patients with solid tumors with MTAP loss. National Library of medicine (US), Available at: https:\/\/clinicaltrials.gov\/study\/NCT06810544 (Accessed 20 April 2026)."},{"key":"10.1016\/j.hoc.2026.09.002_bib76","unstructured":"Determining the dose of regadenoson Most likely to transiently alter the integrity of the blood-brain barrier in patients with high grade gliomas. National Library of medicine (US), Available at: https:\/\/clinicaltrials.gov\/study\/NCT03971734 (Accessed 20 April 2026)."},{"issue":"9","key":"10.1016\/j.hoc.2026.09.002_bib77","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1158\/1078-0432.CCR-18-3729","article-title":"A phase I study of pegylated arginine deiminase (Pegargiminase), cisplatin, and pemetrexed in argininosuccinate synthetase 1-Deficient recurrent high-grade glioma","volume":"25","author":"Hall","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2026.09.002_bib78","unstructured":"A phase II trial of alimta (pemetrexed) in patients with recurrent malignant gliomas, primary central nervous system lymphoma, and brain metastases. National Library of medicine (US), Available at: https:\/\/clinicaltrials.gov\/study\/NCT00276783 (Accessed 20 April 2026)."},{"key":"10.1016\/j.hoc.2026.09.002_bib79","unstructured":"Phase II trial O6-benzylguanine(BG) and Temozolomide(TMZ) therapy of glioblastoma multiforme (glioblastoma) with infusion of autologous P140K MGMT+Hematopoietic progenitors to protect hematopoiesis. National Library of medicine (US), Available at: https:\/\/clinicaltrials.gov\/study\/NCT05052957 (Accessed 20 April 2026)."},{"issue":"4","key":"10.1016\/j.hoc.2026.09.002_bib80","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.002_bib81","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41467-021-21117-3","article-title":"Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma","volume":"12","author":"Jung","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.hoc.2026.09.002_bib82","doi-asserted-by":"crossref","first-page":"E967","DOI":"10.1093\/neuros\/nyz218","article-title":"Phase 0 clinical trial strategies for the neurosurgical oncologist","volume":"85","author":"Sanai","year":"2019","journal-title":"Neurosurgery"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.002_bib83","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11910-024-01338-x","article-title":"Strategies to improve drug delivery across the blood-brain barrier for glioblastoma","volume":"24","author":"Narsinh","year":"2024","journal-title":"Curr Neurol Neurosci Rep"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:25:14Z","timestamp":1791660314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826001127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":83,"alternative-id":["S0889858826001127"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.09.002","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Purine Metabolism as a Therapeutic Target in Glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}